Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01H in previously treated metastatic nonsquamous NSCLC
MOH_2025-02-19_013885Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing R-DXd, I-DXd and Docetaxel (3 arms). Primary endpoints: Objective response rate and Safety and tolerability. Started Feb 2025; status: recruiting.
02
Drugs
raludotatug deruxtecanifinatamab deruxtecandocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2025-02-19_013885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-19_013885.